格隆汇2月27日｜群益证券(香港)研报指出，联影医疗2025年净利YOY+50%，符合预期。国内继续受益 于设备更新政策持续落地，海外市场拓展强化。公司受益于行业恢复，另外叠加公司市占率持续提升， 公司业绩恢复较为明显。国际市场品牌影响力与高端客户渗透率持续提升，全球化布局进一步提速。此 外，随着设备保有量的增加，估计维保业务也可延续较快的增长趋势。公司作为高端医疗设备龙头， AI赋能提升产品力，国内业务恢复，海外市场积极开拓，继续维持"买进"的投资建议。 ...

Group 1 - The medical sector showed strong performance with the largest medical ETF (512170) initially rising over 1% and maintaining positive momentum, outperforming the broader market [1] - Over 1.15 billion CNY of net subscriptions were recorded for the medical ETF, indicating strong investor interest [1] - The ETF has a total scale of 27.7 billion CNY, making it the largest in the medical and healthcare category [3] Group 2 - Huatai Medical reported an expected revenue of 2.584 billion CNY for 2025, representing a year-on-year increase of 25%, with net profit projected at 821 million CNY, up 22% [3] - Other companies within the medical ETF, such as United Imaging and Yirui Technology, are also expected to see net profit growth exceeding 40% [3] - The medical ETF consists of over 50% medical device weight and more than 25% CXO content, covering 12 AI medical and brain-machine interface concept stocks [3] Group 3 - The performance of constituent stocks within the ETF varied, with Huatai Medical leading the gains, rising nearly 7%, while major stocks like Mindray and United Imaging saw declines of nearly 1% [2][3]

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of over 1.15 billion yuan in recent trading sessions [1][5]. Group 1: ETF Performance - The healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1]. - As of February 24, 2026, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year growth of 25%, with a net profit of 821 million yuan, up 22% [3][4]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3]. Group 3: Market Trends - The healthcare sector is characterized by a mix of rising and falling stocks, with Huatai Medical leading gains by rising nearly 7% after a strong earnings report, while major stocks like Mindray and United Imaging saw declines of nearly 1% [1][3].

AI产业链持续走强，算力概念表现活跃，消息面上，全球最大的AI模型API聚合平台OpenRouter数据显 示，9日-15日这周，中国模型以4.12万亿Token的调用量，首次超过同期美国模型的2.94万亿Token，其 中国内四款大模型霸榜全球前五。 中信建投证券指出，目前，AI大模型仍在持续迭代升级，算力需求旺盛，站在中期视角，仍建议持续 重视AI板块。一方面，持续推荐AI算力板块，包括北美算力产业链与国内算力产业链的核心公司；另 一方面，建议关注AI应用板块，特别是端侧AI Agent的进展。此外，也建议关注未来可能边际改善的海 缆及光纤光缆板块、军工通信及商业航天板块，国内外巨头纷纷加码的量子科技板块。 截至2026年2月27日 14:29，上证科创板综合指数(000680)上涨0.20%，成分股普元信息上涨20.01%，沃 尔德上涨20.00%，云天励飞上涨19.97%，明志科技上涨13.69%，赛恩斯上涨13.36%。科创综指ETF鹏 华(589680)上涨0.21%， 冲击3连涨。最新价报1.45元。 科创综指ETF鹏华(589680)，场外联接(A：023757；C：023758。 科创综指E ...

2月26日，"2026年常州—上海经贸交流和创新合作活动周"客商新春交流会在上海举行。这是常州连续第20年在上海举办经贸交流活动。从产业创新到 区域协同，从经贸交流到人文交融，"沪联互通、常来常往"已成为长三角一体化背景下沪常合作共赢的生动注脚。 本次活动周期间，预计达成合作项目28个，投资总额超过194亿元。 王剑锋表示，常州将全面融入全国统一大市场建设，全力营造市场化、法治化、国际化一流营商环境，让每一个项目都能在常州投资安心、发展顺心。 诚挚欢迎更多上海企业和人才选择常州、深耕常州，共同书写长三角一体化发展新篇章。 常州市委书记王剑锋在致辞中表示，上海是改革开放前沿阵地、高质量发展标杆示范，"五个中心"建设动能强劲，持续引领长三角迈向世界级城市群。 常州作为长三角重要中心城市，近年来全方位服务和融入上海大都市圈，经济社会保持稳中有进、向新向优发展态势。 常州宣传部供图 2025年，常州实现地区生产总值近1.12万亿元、增长5.2%；一般公共预算收入715.5亿元，税收占比85.5%，高于全省平均8个百分点、居全省第一；工 业规模超2.2万亿元、全省第三，新能源产业开票突破万亿元，产业底座更加稳固。 面向 ...

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of capital [1][8]. Group 1: ETF Performance - On February 27, the healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1][8]. - The ETF saw a net subscription of over 115 million yuan in the previous day, indicating strong investor interest [1][8]. - As of February 24, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5][12]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year increase of 25%, with a net profit of 821 million yuan, up 22% [3][10]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3][10]. - In contrast, Hotgen Biotech is projected to incur a loss of over 200 million yuan [3][10]. Group 3: Stock Movements - Huatai Medical's stock surged over 11% in early trading, currently leading the sector with a nearly 7% increase [4][10]. - Other stocks like Yingke Medical and Meihua Medical also saw gains, while Jinsong Biological experienced a decline of over 2% [4][10].

Group 1 - The core viewpoint of the article highlights the mixed performance of the technology sector in the A-share market, driven by Nvidia's strong earnings report, but tempered by concerns over market volatility and AI sustainability [1][5][6] - Nvidia reported a revenue of $68.1 billion for Q4 of fiscal 2026, exceeding expectations of $65.91 billion, with a significant year-on-year increase from $39.33 billion [5] - The market remains skeptical about the sustainability of AI spending, with analysts questioning whether AI can deliver tangible cost savings or profits for businesses [6] Group 2 - The ChiNext 50 ETF (588870) experienced fluctuations, with a decline of over 1% in early trading after two consecutive days of gains, reflecting the overall market sentiment [1] - Key stocks within the ChiNext 50 ETF saw mixed performance, with notable declines in companies like Zhongwei Company (down over 4%) and Lanke Technology (down 2%), while Chip Original Co. saw an increase of over 5% [3][4] - The semiconductor industry is showing signs of recovery, with companies like SMIC reporting stable operations and growth in revenue and net profit for Q4 of fiscal 2025 [8] Group 3 - The semiconductor sector is experiencing a divergence in performance, with AI-related segments like computing chips and storage chips seeing strong demand, while non-AI segments are recovering more slowly [6][8] - The ChiNext 50 index has a high exposure to the semiconductor industry, with a weight of 68.3%, capturing significant opportunities in AI chip innovation [9] - The R&D expenditure of the ChiNext 50 index constituents reached 53.23 billion yuan, accounting for 7.93% of revenue, significantly higher than the averages for the Growth Enterprise Market and Main Board [12]

证券之星消息，根据天眼查APP-财产线索数据整理，根据海南省人民医院2月25日发布的《海南省人民 医院2025年先进医疗设备更新项目（一）结果公告（采购包1）》内容显示，上海联影医疗科技股份有 限公司中标，详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 标题：海南省人民医院2025年先进医疗设备更新项目（一）结果公告（采购包1） 采购方：海南省人民医院 供应商：上海联影医疗科技股份有限公司 中标金额：70000000.0,70000000.000000,70000000.00 地区：海南省 发布日期：2026-02-25 通过天眼查大数据分析，上海联影医疗科技股份有限公司共对外投资了21家企业，参与招投标项目9017 次；财产线索方面有商标信息935条，专利信息5626条，著作权信息109条；此外企业还拥有行政许可 457个。 数据来源：天眼查APP ...

国内 AI 医疗进展更新 20260226 摘要 大模型显著提升了医疗 AI 的语言理解和知识密度，使诊疗能力大幅强化， 小尺寸模型在疾病识别与诊断方面已达到或超过一般医生水平，但在罕 见病等顶尖领域仍不及专家。 AI 医疗商业模式更清晰的方向是 B 端提效，围绕医生文书、科研等场景， 医生工作压力大，B 端价值挖掘明确；C 端商业化依赖规模效应，短期 内政策对 AI 处方权放开不乐观，C 端商业化难度高于 B 端。 蚂蚁"阿福"这类医疗超级入口时机选择较好，通过支付宝流量基础和 大量投入，有望打造"超一档"的超级入口，变现基础盘较好，但当前 更偏"价值探索"而非以商业为核心。 C 端互联网医疗主流变现路径集中在卖药与卖服务，但以服务直接变现 不多，更多是导流；入口扩张策略包含 2C 获取用户和与政府医院合作， 占据入口位置后变现可能性增多。 医疗数据变现相对敏感且克制，传统付费方是药企，用于药品研发与临 床应用；平台侧数据资源丰富，可能面向大 B 端提供数据服务，辅助药 企训练与开发药品或药械。 Q&A 近两三年大模型的进展，相比传统 AI 医疗，主要解决了哪些此前难以解决的问 题？ 大模型出现后形成了明显 ...

联影医疗2025年度业绩快报整理 近日，联影医疗发布2025年度业绩快报。 2025年，公司预计实现营业收入138.21亿元，同比增长约34.18%；实现归母净利润18.88亿元，同比增长约 49.60%；实现扣非归母净利润17.88亿元，同比增长约77.01%。 2024年第四季度，预计公司实现营业收入49.62亿元，同比增长约48.30%；实现归母净利润7.68亿元，同比增长约 29.9 联影医疗2025年度业绩快报整理 近日，联影医疗发布2025年度业绩快报。 2025年，公司预计实现营业收入138.21亿元，同比增长约34.18%；实现归母净利润18.88亿元，同比增长约 49.60%；实现扣非归母净利润17.88亿元，同比增长约77.01%。 2024年第四季度，预计公司实现营业收入49.62亿元，同比增长约48.30%；实现归母净利润7.68亿元，同比增长约 29.94%；实现扣非归母净利润7.35亿元，同比增长约34.58%。 报告期内，公司围绕长期竞争力建设，系统推进创新产品导入、全球市场布局深化、供应链体系优化及核心技术 能力积累。 中国市场在大规模医疗设备更新政策于2025年进入常态化、专 ...